Catalent Pharma Solutions, a global provider of advanced drug delivery technologies, has made two senior appointments to strengthen its biologics business.
Andrew Sandford joins the company as Vice President Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings, including the recently completed Biomanufacturing Centre of Excellence in Madison, WI, and its high-performance production cell line offering based on the GPEx system, as well as Catalent’s new SMARTag ADC technology. In addition, he will focus on driving global business and licensing opportunities.
Sandford was previously Vice President of Business Development at Selexis and established the Swiss company's US subsidiary.
Prior to this, he worked with Dow Chemical's Ventures Business Unit; Dowpharma, and Cambrex Biopharma, which was latterly acquired by Lonza Biologics.
Jennifer Mitcham
In a newly created role, Catalent has also appointed Jennifer Mitcham as Director, Business Development for Antibody-Drug Conjugates (ADC), Biologics. She will focus on driving the development pipeline and global customer base for the SMARTag ADC technology.
Mitcham joins the company from Theraclone Sciences where she was Senior Director, Programme Management, responsible for the development of the lead clinical antibody therapeutic programme. Prior to this, Mitcham was with Corixa Corporation where she managed the oncology antibody development portfolio and was a Group Leader in Tumour Antigen Discovery.